Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):648–652. doi: 10.1128/aac.35.4.648

Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist.

E E Camargo 1, S Sostre 1, B Sadzot 1, I Shafique 1, Z Szabo 1, J M Links 1, R F Dannals 1, H N Wagner Jr 1
PMCID: PMC245073  PMID: 1648886

Abstract

We investigated the effects of ofloxacin, a new antibacterial quinolone gamma-aminobutyric acid A receptor antagonist, on the global and regional cerebral metabolic rates of glucose (cMRgl). Twelve healthy normal male volunteers (mean age, 26.7 years) were studied in a double-blind, placebo-controlled protocol of 11 days' duration. Results of a total of 42 positron emission tomography studies were obtained for these subjects: 12 base line, 18 during placebo, and 12 during ofloxacin administration. The conditions under which repeat positron emission tomography studies of the same subject were performed were reproduced as closely as possible. cMRgl was measured in 24 brain regions. The global cMRgl for base line, placebo, and ofloxacin were 8.82 +/- 1.17, 8.24 +/- 1.17, and 8.79 +/- 1.18 mg/min/100 g, respectively (mean +/- 1 standard deviation). The mean global differences between base line and placebo and between ofloxacin and placebo were 5.1 and 6.6%, respectively. Analysis of variance of both the global and the regional cMRgl showed no statistical difference between base-line, placebo, and ofloxacin studies. Variations in cMRgl found in this study were not related to the presence of ofloxacin. Results of our study demonstrate that ofloxacin does not increase or decrease cMRgl beyond the limits of variability of the study.

Full text

PDF
648

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duara R., Grady C., Haxby J., Ingvar D., Sokoloff L., Margolin R. A., Manning R. G., Cutler N. R., Rapoport S. I. Human brain glucose utilization and cognitive function in relation to age. Ann Neurol. 1984 Dec;16(6):703–713. doi: 10.1002/ana.410160613. [DOI] [PubMed] [Google Scholar]
  2. Duara R., Gross-Glenn K., Barker W. W., Chang J. Y., Apicella A., Loewenstein D., Boothe T. Behavioral activation and the variability of cerebral glucose metabolic measurements. J Cereb Blood Flow Metab. 1987 Jun;7(3):266–271. doi: 10.1038/jcbfm.1987.62. [DOI] [PubMed] [Google Scholar]
  3. Engel J., Jr The use of positron emission tomographic scanning in epilepsy. Ann Neurol. 1984;15 (Suppl):S180–S191. doi: 10.1002/ana.410150735. [DOI] [PubMed] [Google Scholar]
  4. Hamacher K., Coenen H. H., Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986 Feb;27(2):235–238. [PubMed] [Google Scholar]
  5. Heiss W. D., Pawlik G., Herholz K., Wagner R., Göldner H., Wienhard K. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab. 1984 Jun;4(2):212–223. doi: 10.1038/jcbfm.1984.30. [DOI] [PubMed] [Google Scholar]
  6. Huang S. C., Phelps M. E., Hoffman E. J., Sideris K., Selin C. J., Kuhl D. E. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980 Jan;238(1):E69–E82. doi: 10.1152/ajpendo.1980.238.1.E69. [DOI] [PubMed] [Google Scholar]
  7. Nistri A., Constanti A. Pharmacological characterization of different types of GABA and glutamate receptors in vertebrates and invertebrates. Prog Neurobiol. 1979;13(2):117–235. doi: 10.1016/0301-0082(79)90016-9. [DOI] [PubMed] [Google Scholar]
  8. Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother. 1982 Oct;22(4):548–553. doi: 10.1128/aac.22.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tallman J. F., Gallager D. W. The GABA-ergic system: a locus of benzodiazepine action. Annu Rev Neurosci. 1985;8:21–44. doi: 10.1146/annurev.ne.08.030185.000321. [DOI] [PubMed] [Google Scholar]
  10. Tsuji A., Sato H., Kume Y., Tamai I., Okezaki E., Nagata O., Kato H. Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother. 1988 Feb;32(2):190–194. doi: 10.1128/aac.32.2.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tyler J. L., Strother S. C., Zatorre R. J., Alivisatos B., Worsley K. J., Diksic M., Yamamoto Y. L. Stability of regional cerebral glucose metabolism in the normal brain measured by positron emission tomography. J Nucl Med. 1988 May;29(5):631–642. [PubMed] [Google Scholar]
  12. Van Caekenberghe D. L., Pattyn S. R. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984 Apr;25(4):518–521. doi: 10.1128/aac.25.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES